Navigation Links
Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
Date:11/6/2009

CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced updated results from a Phase II study of intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung in a poster presentation at the 15th Annual Connective Tissue Oncology Society Meeting held in Miami Beach, Florida, from November 5th to 7th. The poster presentation, entitled "A Phase II Study of Intravenous REOLYSIN (Wild-type Reovirus) in the Treatment of Patients with Bone and Soft Tissue Sarcomas Metastatic to the Lung", was delivered by Dr. Kamalesh Sankhala, part of principal investigator Dr. Monica Mita's team at the Institute of Drug Development (IDD), the Cancer Therapy and Research Center at the University of Texas Health Science Center, (UTHSC), San Antonio, Texas.

The investigators reported that the treatment has been well tolerated to date, and that 19 of 44 evaluable patients experienced stable disease ranging from two to 20 months, resulting in a total clinical benefit rate (complete response + partial response + stable disease) of 43%. The response objective for the study was three or more patients having prolonged stabilization of disease (greater than 6 months) or better, for the agent to be considered. The trial exceeded its established objective with six patients experiencing stable disease for more than six months. Two patients have experienced stable disease for more than 19 months. One has synovial cell sarcoma that relapsed following surgery, while the other has Ewing's Sarcoma and had previously progressed following multiple treatments.

"We were very happy to participate in the study," said Dr. Mita. "REOLYSIN is a promising option for patients with sarcoma as shown by the results of this study. As a single agent the virus had a clinical benefit rate of 43% and it was very well tolerated. Further studies combining REOLYSIN with chemotherapy are contempl
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... DIEGO , June 30, 2015  The ... Education in Biosciences (CCE/Bio) and UC San Diego ... fermentation, to be held Aug.  12 – 14, ... ).  This three-day workshop provides an intense exposure ... industrial biotechnology, and is well-suited to biologists, process ...
(Date:6/30/2015)...  The Dr. Samadi Prostate Cancer Center in ... suite of new genetic testing methods for men with an ... cancer. Dr. Samadi,s Prostate Cancer Center ... the risk and optimizing the diagnosis of prostate cancer, both ... now offer these revolutionary genetic tests to men with an ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... media company, launched “Cannavoices,” an unprecedented digital video and broadcast initiative. Produced by ... the most dynamic collection of legal medical cannabis stories ever assembled. , ...
(Date:6/29/2015)... KY and Manhattan, KS (PRWEB) , ... June ... ... has acquired US PATENT 7736892 B2. Under the terms of the agreement, MediVet ... Umbilical Cord Matrix Stem Cells (UCMSCs). MB-007 is currently in pre-clinical development as ...
Breaking Biology Technology:UC San Diego Extension to Offer Third Annual Microbial Fermentation Workshop 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 4New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 5Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3MediVet Biologics Acquires Exclusive Patent License from Kansas State University 2MediVet Biologics Acquires Exclusive Patent License from Kansas State University 3
... of the fruit fly and roundworm,s functional genomic elements: DNA ... which genes are turned on and off at various times ... of the Human Genome Project, the genomes of the fruit ... elegans , are powerful models for understanding human biology ...
... (Nasdaq: NEOG ) announces the following Webcast:What: ... January 4, 2011 @ 11:00 ETWhere: , http://www.videonewswire.com/event.asp?id=75037 ... on to the web at the address above.  Contact: ... are unable to participate during the live webcast, the ...
... (December 21, 2010) -- A researcher known widely ... and use of minimally toxic, environmentally friendly chemicals ... Dr. Paul Anastas, science advisor to the ... for the EPA,s Office of Research and Development ...
Cached Biology Technology:Scientists reveal how biological activity is regulated in fruit fly and roundworm genomes 2Scientists reveal how biological activity is regulated in fruit fly and roundworm genomes 3Scientists reveal how biological activity is regulated in fruit fly and roundworm genomes 4Science advisor to the US EPA to speak to industry, academic leaders on sustainability innovations 2Science advisor to the US EPA to speak to industry, academic leaders on sustainability innovations 3
(Date:6/24/2015)... MARTIGNY, Switzerland , June 24, 2015 /PRNewswire/ ... strategic partnership with emerging biometric password solution one ... http://photos.prnewswire.com/prnh/20150623/225014LOGO one face in, ... offers a ground-breaking and affordable multifactor-authentication biometric answer ... speaker recognition technology, provided in partnership with KeyLemon, ...
(Date:6/23/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/vq2k2f/bodyworn ... "Body-Worn Temperature Sensors Market - Global Industry Analysis, ... 2020" report to their offering. ... body-worn temperature sensors market. The global body-worn temperature ... of types, care setting, patient demographic, applications and ...
(Date:6/23/2015)... BEACH GARDENS, Fla. , June 23, ... multi-factor identity management and authentication solutions, today announced ... Altus strong, multi-factor authentication solution.  The enhancements ... of use of the DigitalPersona Altus platform ... biometric reader compatibility. In today,s ...
Breaking Biology News(10 mins):KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2
... Hospital scientists has identified a possible new approach to ... component in a bid to invigorate the immune response. ... function of one of the innate immune molecules is ... response to infections and other threats. Investigators showed the ...
... Albert Einstein College of Medicine of Yeshiva University ... development of myelodysplastic syndromes (MDS), serious blood diseases that are ... leukemia. The findings could lead to targeted therapies against MDS ... the online edition of the journal Blood . ...
... The next "next-gen" technology in genome sequencing has gotten a ... Cold Spring Harbor Laboratory (CSHL) and collaborators today published results ... which was recently introduced but whose use has so far ... by CSHL Assistant Professor Michael Schatz and Adam Phillippy and ...
Cached Biology News:Innate immune system protein provides a new target in war against bacterial infections 2Innate immune system protein provides a new target in war against bacterial infections 3Myelodysplastic syndromes (MDS) linked to abnormal stem cells 2An error-eliminating fix overcomes big problem in '3rd-gen' genome sequencing 2An error-eliminating fix overcomes big problem in '3rd-gen' genome sequencing 3
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Rabbit polyclonal to pCrosstide (HRP) ( Abpromise for all tested applications)....
IkappaB-alpha (112B2) Mouse mAb...
Human sIL-2R/CD25 ELI-PAIR Kit...
Biology Products: